Contained therein are details of cloning, protein expression and purification, crystallization and structure determination methods used.
Chloroquine (CQ) has been widely used in the treatment of malaria since the 1950s, though toxicity and resistance is increasingly limiting its use in the clinic. More recently, CQ is also becoming recognized as an important therapeutic compound for the treatment of autoimmune disorders and has shown activity as an anticancer agent. However, the full extent of CQ pharmacology in humans is still unclear. Herein, we demonstrate that the lysosomal protein saposin B (sapB), critical for select lipid degradation, binds CQ with implications for both CQ function and toxicity. Using isothermal titration calorimetry (ITC) and fluorescence quenching experiments, CQ was shown to bind to the dimeric form of sapB at both pH 5.5 and pH 7.4 with an average binding affinity of 2.3 10 4 m À1 . X-ray crystallography confirmed this, and the first complete crystal structure of sapB with a bound small molecule (CQ) is reported. The results suggest that sapB might play a role in mitigating CQbased toxicity and that sapB might itself be overwhelmed by CQ causing impaired lipid degradation. Chloroquine (CQ) was first synthesized in 1934 by the Bayer scientist Johann Anderstag and initially given the name resorchin (RESORcinate of 4-aminoCHINolin). [1] Originally deemed too toxic for use in humans, it was rediscovered in the 1940s and has been widely used against malaria, with a high degree of success, since the 1950s. [2] Several side effects result from excessive use of CQ, such as gastrointestinal distress, retinopathy, cardiac toxicity, and even death. [3, 4] These contraindications are likely due to CQ being a noted negative ionotrope, vasodilator, and inhibitor of intraventricular conduction. [2] Ma-laria treatment requires high doses of CQ (up to 1 500 mg) over several days. [5, 6] In meta analyses, it has been shown that 5 g of ingested CQ is almost invariably fatal if not counteracted (charcoal flushing, use of diazepam and adrenaline), and even 2 g has been reported to be fatal in some cases, accounting for the relatively high morbidity associated with CQ treatment. [7] [8] [9] [10] CQ dosage is recommended based on weight, but most patients are simply given a set dose. [7] In addition to acute toxicity upon ingestion, CQ has toxicity, particularly the development of retinal maculopathy, [8] associated with prolonged use (a cumulative dose of > 100 g and duration of treatment > 1 year). Chronic CQ use has been shown to cause lysosomal dysfunction in retinal pigment epithelial cells with associated rise in lysosome pH and an increase in lysosome/phagosome accumulation of rod outer segments, a marker of degradation.
The emergence of CQ-resistant malarial strains coupled to its toxicity has limited CQ use in recent years, particularly in regions of Africa, Southeast Asia, and large portions of South America. However, low doses of CQ are under investigation for different therapeutic applications, with CQ now used for the treatment of lupus, [11] rheumatic disease, [12] sarcoidosis, [13] and postulated for use in cancer therapy. [14] In order to optimize the use of CQ as a therapeutic agent, the mechanisms of CQ transport, activity, and toxicity need to be more fully elucidated.
To date, the full mechanism of action of CQ is unknown, but it is accepted that CQ is a lysosomotropic agent that interferes with cellular processes by raising lysosomal pH. [15] It is likely that CQ toxicity mitigating processes exist in the human lysosome; however, their mechanisms of action are not known.
Saposin B (sapB) is a lysosomal protein and one of the most studied members of the saposin protein family. [16] Li and coworkers have demonstrated that sapB is involved in the hydrolysis of glycolipids and glycerolipids. [17] A deficiency in sapB results in the accumulation of lipids in the lysosome and results in the lysosomal storage disease metachromatic leukodystrophy. [18] SapB is unique in the saposin family in that it facilitates degradation by interacting with the substrate, not the enzymes, with sapB having no direct effect on substrate hydrolysis. [19] We [20, 21] and others, [22] have demonstrated that sapB can bind coenzyme Q10 (CoQ10) with preferred binding at pH 5.5. Such binding is important in the removal of 'damaged' CoQ10 from membranes and possible subsequent transport for excretion. Most recently, Yamamoto et al. demonstrated that prosaposin and/or sapB can actually regulate CoQ10 levels in human cells (HepG2 hepatocytes). [23] It occurred to us that, given the lysosomal accumulation of CQ and the structural similarities between CoQ10 and CQ, sapB might bind CQ with relevant physiological consequences.
Herein, we investigate the binding of sapB with CQ using isothermal titration calorimetry (ITC), fluorescence quenching experiments, and X-ray crystallography. Our results indicate significant binding between sapB and CQ, at both pH 5.5 and pH 7.4, akin to that of CoQ10. An X-ray crystal structure of the sapB-CQ complex is also reported and shows the presence of one CQ molecule per sapB dimer, in accordance with our binding studies. The data is discussed in terms of possible implications on the toxicity of CQ.
The expression and purification of sapB is described elsewhere. [21] The apparent thermodynamic parameters of CQ binding to sapB in buffered aqueous solution of 20 mm phosphate at pH 5.5 and pH 7.4 were obtained by ITC and fluorescence spectroscopy. The integrated heats (mJ) for each injection versus the molar ratio of CQ to sapB dimer are shown in Figure 1 . Control titrations of CQ into buffer were performed and used in the analysis. The ITC data were obtained using a reaction volume of 185 mL on a nano-isothermal titration calorimeter (TA Instruments) whereby downward negative peaks correspond to an endothermic reaction. We note that all reported thermodynamic quantities in this study are apparent values (i.e., experimentally measured values under nonstandard conditions), which may include possible contributions to the overall equilibrium from different processes such as structural rearrangements of protein-substrate complexes upon interaction and substrate and buffer species in different states of protonation. The heats at the end of these titrations were in excess of the heat of dilution from adding CQ into buffer suggesting the presence of additional weak binding to the protein or protein-protein association and/or oligomerization. [24] Accordingly, a model of two sets of independent binding sites, one strong and one weak, was used to curve-fit the data, and the derived experimental thermodynamic parameters for the strong sites are summarized in Table 1 . Due to the weak nature of the second set of sites, the individual thermodynamic parameters could not be determined and only the product of the three parameters, n 2 ·K 2,ITC ·DH 2,ITC , is reported. Similar ITC results were obtained at pH 5.5 ( Table 1 ). The ITC data indicate that one CQ molecule binds per sapB dimer with a binding affinity (K ITC ) in the order of~3 10 4 m À1 ( Table 1 ). The binding is entropically driven whereby the observed large and positive change in the entropy (DS ITC ) of binding is ascribed to changes in the hydration state of the protein and the ligand (i.e., release of water molecules) upon ligand binding.
To corroborate the ITC results, fluorescence quenching studies were performed between sapB and CQ in 20 mm phosphate buffer at pH 5.5 and pH 7.4. The quenching of the emission intensity of tryptophan and tyrosine residues of sapB at 325 nm was monitored on a Varian Cary Eclipse spectrofluorimeter with increasing concentrations of CQ. The experimental conditions are reported in the caption of Figure 2 .
For a static quenching process, when small molecules bind independently to a set of equivalent sites on a macromolecule, the equilibrium between free and bound molecules is given by Equation (1), where K a is the binding constant, n is the number of binding sites on the protein, Q is the quencher concentration (i.e., CQ), and F 0 and F are the steady-state fluorescence intensities in the absence and in the presence of the quencher, respectively. 
The values of n (slope) and logK a (intercept) can be obtained from the double logarithm plot shown in Figure 2 and are reported in Table 1 . The data in Figure 2 reflect the effect of CQ on the fluorescence intensity of sapB and show a binding stoichiometry of one CQ per sapB dimer and a binding affinity close to 1 10 4 m À1 , consistent with the ITC results. Note that the lowest fluorescence emission curve (blue curve in Figure 2 ) is that of CQ alone in buffer showing minimal interference with the emission spectrum of the protein at 325 nm. Upon binding to sapB, a red-shift in the emission peaks of sapB and CQ is observed suggesting the formation of a protein-ligand complex and a change in the microenvironment of the protein binding site. Similar observations were noted at pH 5.5 (Table 1) , which is the pH of the lysosome where sapB is found; however, a notable change in the peak shapes was observed and is likely due to the change in pH. Nonetheless, both ITC and fluorescence quenching studies showed similar binding stoichiometry and affinity between CQ and sapB at both pH values tested (Table 1) .
Initial attempts to crystallize and resolve a crystal structure from the expressed and purified sapB used in the ITC and fluorescence measurements with CQ were unsuccessful. Poor crystal quality and limited diffraction were likely due to the presence of a noncleavable polyhistidine tag used in purification. This is not unexpected because the His 6 tag is unstructured and likely impedes crystal packing. As a result, the protein was re-expressed with a tobacco etch virus (TEV) protease cleavage site introduced after the His 6 tag. Once the protein was newly expressed and purified via immobilized metal affinity chromatography (IMAC), the affinity tag was cleaved with AcTEV protease and crystal screening was conducted. SapB in complex with CQ crystallized in the P3221 space group (for additional crystallographic data, see Table 2 ). The crystal structure of sapB with bound CQ is shown below (Figure 3) .
The crystal structure is in support of the ITC and fluorescence quenching data confirming that the binding of CQ to sapB does indeed occur and is dependent upon proper dimerization of sapB. A close-up view of the active site and the amino acid residues forming the binding pocket for CQ is shown in Figure 3 b. The CQ binding pocket is largely hydrophobic with contributions of Leu 73, Met 61 and Met 65 residues from one monomer and Arg 38 and Glu 35 residues from the second partner monomer. Arg 38 and Glu 35 are involved in a salt bridge, and the aliphatic portion of Arg 38 additionally forms a wall of the active site pocket. Glu 69 is involved in a potential hydrogen-bonding interaction with CQ as indicated by the dotted yellow line in Figure 3 
There are two possible conformations of the CQ molecule within the binding pocket based on the electron density (Figure 3 b) . While the CQ chain undergoes minor conformational changes, the heterocyclic moiety is shown to exhibit two conformations based on the crystal structure. Residue Glu 69 of one sapB monomer appears to interact with CQ in either conformation through a hydrogen-bonding interaction. Met 65 and Leu 73 appear to help sequester the hydrophobic tail of the CQ molecule.
Initial mutagenesis studies focused on Glu 69 were conducted to explore whether this residue plays any major role in the binding of CQ to sapB. We prepared a sapB variant (E69A) and performed additional binding studies. Figure 4 shows an ITC titration and a fluorescence quenching experiment between CQ and sapB mutant E69A at pH 5.5 and 7.4, respectively. The re- [a] Refers to highest resolution shell.
ChemMedChem 0000, 00, 0 -0 www.chemmedchem.org sults were similar to those observed with wild-type sapB (Table 3 ), suggesting a relatively minor role of residue Glu 69 in the interaction of CQ with sapB. The binding reaction is still strongly entropically favored as indicated by the large and positive value of DS ITC . It is likely that the hydrophobic residues lining the substrate binding site play a larger role in substrate specificity and binding. Overall, the sapB-CQ crystal structure supports the conclusion that two sapB monomers come together to bind to a single CQ molecule, at least under the conditions of the structure obtained in the solid state. This conclusion is supported by ITC and fluorescence quenching experiments performed at pH 5.5 and pH 7.4.
As noted earlier, we recently reported the binding of sapB with CoQ10 using ITC and fluorescence spectroscopy. [20] The ITC binding parameters of CoQ10 and CQ with sapB at lysosomal pH 5.5 exhibit some degrees of similarities (Table 3 ). In both cases, the binding stoichiometry is one molecule per sapB dimer, and the reaction is strongly entropy favored. The binding affinity of CoQ10 to sapB (~10 7 m À1 ) is approximately three orders of magnitude greater than that of CQ (~10 4 m À1 ), which might reflect the high hydrophobicity of the binding pocket of sapB and of CoQ10.
SapB with bound CoQ10 has been observed in human urine, [22] and it has been demonstrated that sapB can regulate CoQ10 levels in the cell. [23] As such, the fact that we have observed significant CQ binding by sapB, albeit weaker compared with CoQ10, is consistent with our hypothesis that sapB might play a role in removing CQ from the body and in controlling CQ levels in the cell.
In summary, our results demonstrate CQ is bound by sapB at pH 5.5 and pH 7.4 with an average binding affinity of 2.3 10 4 m À1 . In addition to providing the first complete crystal structure of sapB with a bound small-molecule substrate (a partial sapB-lipid structure has been reported by Ahn et al. [24] ), our study provides further evidence of the substrate multispecificity of sapB, now having been shown to bind a range of substrates from lipid [17] to CoQ10 [20] to drugs such as atovaquone [20] and now CQ. The implications of the work are twofold: 1) that sapB might play a role in mitigating CQ-based toxicity, and 2) that sapB might itself be 'overwhelmed' by CQ, especially over prolonged periods of time and depending on the dose administered, with the consequence being impaired lipid degradation. CQ has already been show to impair autophagic protein degradation, [25] so the questions of whether lipid buildup occurs (over prolonged use) is an intriguing one. Moving forward, we will conduct extensive mutagenesis studies to explore the importance of select residues lining the active site and to determine their roles in both binding and substrate selectivity. This work also suggests the possibility that sapB-CQ could be found in the urine of patients taking CQ, and we are actively engaged in pursing this question. Finally, experiments to investigate whether sapB can actually change/control CQ levels and whether lipid build-up occurs in human cells will also be explored. 
